Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150664 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
A Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Compass Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
- 7
- Study locations
NCT06150664 is a Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Compass Therapeutics. The registered enrollment target is 73 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT06150664, a Phase 1 study of Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Compass Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Conditions Studied
Interventions
- DRUG CTX-8371
Study Locations (7)
Florida
- D&H Cancer Research Center - Margate
- Florida Cancer Specialists - Lake Nona - Orlando
- Florida Cancer Specialists - Sarasota - Sarasota
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Roswell Park Cancer Institute - Buffalo
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06150664
The ClinicalTrials.gov registry entry for NCT06150664 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Compass Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CTX-8371 is the first listed.
NCT06150664 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06150664 about?
NCT06150664 is a clinical study titled "A Phase 1 of CTX-8371 in Patients With Advanced Malignancies". This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
What is the current status of trial NCT06150664?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2024-03-19. Estimated completion is 2027-05.
What conditions does trial NCT06150664 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hodgkin Lymphoma, Malignant Melanoma.
What interventions are being tested in trial NCT06150664?
The interventions under investigation include: CTX-8371 (DRUG).
Who is sponsoring clinical trial NCT06150664?
This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150664 being conducted?
This trial has 7 study locations across Florida, Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.